What happened in optometry this week: February 3 - February 7
Catch up on what happened in optometry during the week of February 3-February 7.
Catch up with what Optometry Times shared this week:
Lumenis unveils OptiLIFT for lower lid laxity and impaired blinking
By Emily Kaiser Maharjan, Assistant Managing Editor
Lumenis, creator of OptiLIGHT, has revealed a new addition to their portfolio: OptiLIFT, a noninvasive device that leverages Dynamic Muscle Stimulation (DMSt™) technology to tone facial muscles and improve lower lid laxity and thus impaired blinking. The device is now available in the United States and will follow in additional markets.1
OptiLIFT uses proprietary DMSt, which, as the name implies, stimulates muscles in the periorbital area with electrical impulses to tighten and tone. Over time, the muscle strengthens, improving function of the lower eyelid. The reduction in lid laxity was investigated in a recent clinical study, led by James Chelnis, MD, FACS, and the results showed 75% reduction in lid laxity, 70% improvement in blinking quality, and a 286% increase in tear breakup time following use of OptiLIFT.2
Positive topline results from Qlaris Bio Phase 2 clinical trials find QLS-111 demonstrates IOP-lowering activity in patients with POAG, OHT
By Jordana Joy, Associate Editor
Clinical stage biotechnology company Qlaris Bio announced positive topline results from 2 of its US Phase 2 clinical trials investigating QLS-111 in patients with primary open angle glaucoma (POAG) and ocular hypertension (OHT).1 Osprey and Apteryx, the masked, randomized Phase 2 trials, successfully met all primary and secondary endpoints, according to a news release.
Nuance Audio hearing aid glasses receive FDA approval as a medical device
By Emily Kaiser Maharjan, Assistant Managing Editor
EssilorLuxottica has received medical device approval from the FDA for its over-the-counter Nuance Audio Glasses, which integrates open-ear hearing aid into a pair of smart glasses. Concurrently, the device received CE marking under the Medical Devices Regulation in the EU as well as an ISO Quality Management System certification for Hearing Aids. The sweep of approvals will allow the glasses to launch in the US and Europe simultaneously.1
The dual advantage of a shorter lens replacement schedule
By Janelle Davison, OD
As an eye care provider with a patient-first approach, I prefer shorter wear cycles for contact lenses, which may deliver improvements in comfort1 and overall patient compliance.2 What’s more, the residual business benefits of the resulting increased patient compliance and comfort3 correlate to better patient outcomes, satisfaction, and loyalty,4-6 and reduce the risk factors that may contribute to lens dropout.7 Though a shorter lens replacement schedule, such as for a daily disposable, has many advantages, some patients still require reusable lenses for various reasons. With increased innovations coming to market, new reusable lenses with shorter replacement intervals, such as a 1-week schedule, have the potential to satisfy the unmet needs of patients and providers alike.
FDA approves ranibizumab for the treatment of diabetic macular edema via continuous delivery implant
By Martin David Harp, Associate Editor, Ophthalmology Times
The US Food and Drug Administration (FDA) has approved ranibizumab injection) 100 mg/mL (Susvimo; Genentech) for the treatment of diabetic macular edema (DME). The company noted that Susvimo is the “first and only FDA-approved treatment shown to maintain vision in people with DME with fewer treatments than standard-of-care eye injections.”
